Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth.

Chen C, Wei X, Rao X, Wu J, Yang S, Chen F, Ma D, Zhou J, Dackor RT, Zeldin DC, Wang DW.

J Pharmacol Exp Ther. 2011 Feb;336(2):344-55. doi: 10.1124/jpet.110.174805.

2.

Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance.

Xu M, Ju W, Hao H, Wang G, Li P.

Drug Metab Rev. 2013 Aug;45(3):311-52. doi: 10.3109/03602532.2013.806537. Review.

PMID:
23865864
3.

Roles of the epoxygenase CYP2J2 in the endothelium.

Askari A, Thomson SJ, Edin ML, Zeldin DC, Bishop-Bailey D.

Prostaglandins Other Lipid Mediat. 2013 Dec;107:56-63. doi: 10.1016/j.prostaglandins.2013.02.003. Review.

4.

Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy.

Karkhanis A, Hong Y, Chan EC.

Biochem Pharmacol. 2017 Feb 23. pii: S0006-2952(17)30094-1. doi: 10.1016/j.bcp.2017.02.017. [Epub ahead of print] Review.

PMID:
28237650
5.

The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.

Xu X, Zhang XA, Wang DW.

Adv Drug Deliv Rev. 2011 Jul 18;63(8):597-609. doi: 10.1016/j.addr.2011.03.006. Review.

PMID:
21477627
6.

Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.

Shahabi P, Siest G, Visvikis-siest S.

Drug Metab Rev. 2014 Feb;46(1):33-56. doi: 10.3109/03602532.2013.837916. Review.

PMID:
24040964
7.

Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease.

Spiecker M, Liao J.

Trends Cardiovasc Med. 2006 Aug;16(6):204-8. Review.

PMID:
16839864
8.

CYP epoxygenase derived EETs: from cardiovascular protection to human cancer therapy.

Chen C, Wang DW.

Curr Top Med Chem. 2013;13(12):1454-69. Review.

PMID:
23688135

Supplemental Content

Support Center